{"organizations": [], "uuid": "c67a0fd41c21fcd757eb012deb7de19358ca4589", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180213.html", "section_title": "Archive News &amp; Video for Tuesday, 13 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-shanghai-fosun-pharmaceutical-grou/brief-shanghai-fosun-pharmaceutical-group-unit-gets-sole-license-on-research-of-anticarcinogen-in-china-idUSL4N1Q427G", "country": "US", "domain_rank": 408, "title": "Shanghai Fosun Pharmaceutical Group unit gets sole license on research of anticarcinogen in China", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.982, "site_type": "news", "published": "2018-02-14T12:24:00.000+02:00", "replies_count": 0, "uuid": "c67a0fd41c21fcd757eb012deb7de19358ca4589"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-shanghai-fosun-pharmaceutical-grou/brief-shanghai-fosun-pharmaceutical-group-unit-gets-sole-license-on-research-of-anticarcinogen-in-china-idUSL4N1Q427G", "ord_in_thread": 0, "title": "Shanghai Fosun Pharmaceutical Group unit gets sole license on research of anticarcinogen in China", "locations": [], "entities": {"persons": [], "locations": [{"name": "china", "sentiment": "none"}, {"name": "beijing", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "shanghai fosun pharmaceutical group co ltd", "sentiment": "negative"}, {"name": "shanghai fosun pharmaceutical group", "sentiment": "negative"}, {"name": "thomson reuters trust principles", "sentiment": "none"}, {"name": "galaxy biotech, llc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 14 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd :\n* Says its unit signs License and Option Agreement with U.S. company Galaxy Biotech, LLC, to get sole license on research and development of monoclonal antibody for anticarcinogen new drug in China\nSource text in Chinese: goo.gl/JmZvq6\nFurther company coverage: (Beijing Headline News)\n ", "external_links": ["https://goo.gl/JmZvq6", "http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-14T12:24:00.000+02:00", "crawled": "2018-02-14T12:25:10.063+02:00", "highlightTitle": ""}